BACKGROUND: A consensus statement recommends initial intravenous (IV) vancomycin dosing of 15-20 mg/kg every 8- 24 hours, with an optional 25- to 30-mg/kg loading dose. Although some studies have shown an association between weight and the development of vancomycin-associated nephrotoxicity, results have been inconsistent. OBJECTIVE: To evaluate the correlation between incidence of nephrotoxicity associated with weight-based IV vancomycin dosing strategies in nonobese and obese patients. METHODS: This retrospective cohort study evaluated hospitalized adult patients admitted who received IV vancomycin. Patients were stratified into nonobese (body mass index [BMI] <25 kg/m2), obesity class I and II (BMI 30-39.9kg/m2), and obesity class III (BMI≥40 kg/m2) groups; patients who were overweight but not obese were excluded. Incidence of nephrotoxicity and serum vancomycin trough concentrations were evaluated. RESULTS: Of a total of 62 documented cases of nephrotoxicity (15.1%), 13 (8.7%), 23 (14.3%), and 26 (26.3%) cases were observed in nonobese, obesity class I and II, and obesity class III groups, respectively ( P=0.002). Longer durations of therapy ( P<0.0001), higher initial maintenance doses in both total milligrams/day ( P=0.0137) and milligrams/kilogram ( P=0.0307), and any trough level >20 mg/L ( P<0.0001) were identified as predictors of development of nephrotoxicity. Concomitant administration of piperacillin/tazobactam, diuretics, and IV contrast were associated with development of nephrotoxicity ( P<0.005, all). Patients with class III obesity were 3-times as likely to develop nephrotoxicity when compared with nonobese patients (odds ratio [OR]=2.99; CI=1.12-7.94) and obesity class I and II patients (OR=3.14; CI=1.27-7.75). CONCLUSIONS: Obesity and other factors are associated with a higher risk of vancomycin-associated nephrotoxicity.
BACKGROUND: A consensus statement recommends initial intravenous (IV) vancomycin dosing of 15-20 mg/kg every 8- 24 hours, with an optional 25- to 30-mg/kg loading dose. Although some studies have shown an association between weight and the development of vancomycin-associated nephrotoxicity, results have been inconsistent. OBJECTIVE: To evaluate the correlation between incidence of nephrotoxicity associated with weight-based IV vancomycin dosing strategies in nonobese and obesepatients. METHODS: This retrospective cohort study evaluated hospitalized adult patients admitted who received IV vancomycin. Patients were stratified into nonobese (body mass index [BMI] <25 kg/m2), obesity class I and II (BMI 30-39.9kg/m2), and obesity class III (BMI≥40 kg/m2) groups; patients who were overweight but not obese were excluded. Incidence of nephrotoxicity and serum vancomycin trough concentrations were evaluated. RESULTS: Of a total of 62 documented cases of nephrotoxicity (15.1%), 13 (8.7%), 23 (14.3%), and 26 (26.3%) cases were observed in nonobese, obesity class I and II, and obesity class III groups, respectively ( P=0.002). Longer durations of therapy ( P<0.0001), higher initial maintenance doses in both total milligrams/day ( P=0.0137) and milligrams/kilogram ( P=0.0307), and any trough level >20 mg/L ( P<0.0001) were identified as predictors of development of nephrotoxicity. Concomitant administration of piperacillin/tazobactam, diuretics, and IV contrast were associated with development of nephrotoxicity ( P<0.005, all). Patients with class III obesity were 3-times as likely to develop nephrotoxicity when compared with nonobese patients (odds ratio [OR]=2.99; CI=1.12-7.94) and obesity class I and II patients (OR=3.14; CI=1.27-7.75). CONCLUSIONS:Obesity and other factors are associated with a higher risk of vancomycin-associated nephrotoxicity.
Entities:
Keywords:
body mass index; infection; nephrotoxicity; obesity; patient safety; therapeutic drug monitoring; vancomycin
Authors: Heather D'Amico; Katie L Wallace; Donna Burgess; David S Burgess; Sarah Cotner; Ryan Mynatt; Nannan Li; Arnold Stromberg; Jeremy VanHoose Journal: Antimicrob Agents Chemother Date: 2021-10-11 Impact factor: 5.938
Authors: Lakshmi Pulakat; Howard H Chen; Madhavi P Gavini; Lauren A Ling; Yinian Tang; Alexander Mehm; Gregory L Martin; Corinna N Beale; Brian P Mooney; Hongmin Sun Journal: Pharmaceutics Date: 2022-04-30 Impact factor: 6.525
Authors: Hilary R Teaford; Ryan W Stevens; Andrew D Rule; Kristin C Mara; Kianoush B Kashani; John C Lieske; John O'Horo; Erin F Barreto Journal: Antimicrob Agents Chemother Date: 2020-12-16 Impact factor: 5.191
Authors: Anat Stern; Carolyn D Alonso; Carolina Garcia-Vidal; Celia Cardozo; Monica Slavin; Michelle K Yong; Su Ann Ho; Seema Mehta Steinke; Robin K Avery; Philipp Koehler; Christof Scheid; Oliver A Cornely; Johan Maertens; Yasmine Abi Aad; David J Epstein; Genovefa A Papanicolaou; Dionysios Neofytos Journal: J Antimicrob Chemother Date: 2021-10-11 Impact factor: 5.790